temozolomide has been researched along with Fatigue in 7 studies
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC)." | 9.20 | Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. ( Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H, 2015) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 9.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC)." | 5.20 | Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. ( Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H, 2015) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 5.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "Bortezomib was administered on days 2, 5, 9, and 12; temozolomide on days 1-5 of a 28-day cycle." | 2.77 | A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ( Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minniti, G | 1 |
| Scaringi, C | 1 |
| Baldoni, A | 1 |
| Lanzetta, G | 1 |
| De Sanctis, V | 1 |
| Esposito, V | 1 |
| Enrici, RM | 1 |
| Saif, MW | 1 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Rodriguez, T | 1 |
| Gabrielson, A | 1 |
| Tesfaye, AA | 1 |
| Marshall, JL | 1 |
| Pishvaian, MJ | 1 |
| Smaglo, B | 1 |
| Jha, R | 1 |
| Dorsch-Vogel, K | 1 |
| Wang, H | 1 |
| He, AR | 1 |
| Schiff, D | 1 |
| Desjardins, A | 1 |
| Cloughesy, T | 1 |
| Mikkelsen, T | 1 |
| Glantz, M | 1 |
| Chamberlain, MC | 1 |
| Reardon, DA | 1 |
| Wen, PY | 1 |
| Portnow, J | 1 |
| Frankel, P | 1 |
| Koehler, S | 1 |
| Twardowski, P | 1 |
| Shibata, S | 1 |
| Martel, C | 1 |
| Morgan, R | 1 |
| Cristea, M | 1 |
| Chow, W | 1 |
| Lim, D | 1 |
| Chung, V | 1 |
| Reckamp, K | 1 |
| Leong, L | 1 |
| Synold, TW | 1 |
| Taphoorn, MJ | 1 |
| Stupp, R | 1 |
| Coens, C | 1 |
| Osoba, D | 1 |
| Kortmann, R | 1 |
| van den Bent, MJ | 1 |
| Mason, W | 1 |
| Mirimanoff, RO | 1 |
| Baumert, BG | 1 |
| Eisenhauer, E | 1 |
| Forsyth, P | 1 |
| Bottomley, A | 1 |
| Rivera, E | 1 |
| Meyers, C | 1 |
| Groves, M | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Arun, B | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Hortobagyi, GN | 1 |
| Buchholz, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib[NCT01205828] | Phase 2 | 16 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Lack of efficacy) | ||
| A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors[NCT00544284] | Phase 1 | 25 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
complete response at any time + partial response at any time + stable disease after 8 weeks of treatment based on RECIST Criteria (NCT01205828)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| ABT-888 and Temozolomide | 3 |
Record of all toxicities graded according to the NCI CTCAE version 3.0 (NCT01205828)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| ABT-888 and Temozolomide | 5 |
the number of months between a patient's enrollment and his/her date of death (NCT01205828)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| ABT-888 and Temozolomide | 13.1 |
The number of months between a patient's enrollment and his/her disease progression (NCT01205828)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| ABT-888 and Temozolomide | 1.9 |
6 trials available for temozolomide and Fatigue
| Article | Year |
|---|---|
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellul | 2015 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are | 2012 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
1 other study available for temozolomide and Fatigue
| Article | Year |
|---|---|
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |